Polypill Not Linked to Reduced Cognitive Decline in Seniors

MONDAY, Jan. 30, 2023 (HealthDay News) -- A polypill (antihypertensives and a statin) does not reduce cognitive decline but is associated with reduced functional decline for adults aged 65 years and older with cardiovascular risk factors, according to a study published online Jan. 30 in JAMA Neurology.
Jacqueline J. Bosch, Ph.D., from McMaster University and Hamilton Health Sciences in Canada, and colleagues examined whether a polypill could reduce cognitive and functional decline in 2,098 people aged 65 years or older, with risk factors but without cardiovascular disease.
Overall, 86 and 32 percent of participants had hypertension and impaired fasting plasma glucose levels, respectively. The researchers found that the mean baseline systolic blood pressure was 146.1 mm Hg and the mean low-density lipoprotein cholesterol level was 124.3 mg/dL; among those assigned to the polypill group, decreases of 5.7 mmHg and 24 mg/dL, respectively, were seen. No significant differences were seen between the treatment groups in the number of participants who experienced substantive cognitive decline or dementia during a five-year follow-up. For those assigned to the polypill versus placebo or polypill plus aspirin versus double placebo, functional decline was reduced during follow-up.
"Although mean change in score for any cognitive measure was not different between groups, there was a significant difference in mean functional decline between the groups at study end for both the polypill versus placebo and the polypill plus aspirin versus placebo comparisons," the authors write.
Several authors disclosed financial ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Related Posts
Moderna ofrecerá vacunas contra la COVID gratis a las personas sin seguro tras el final de la emergencia
JUEVES, 16 de febrero de 2023 (HealthDay News) -- Los adultos estadounidenses...
Un estudio encuentra que las tasas de tratamiento para la adicción a los opioides se han estancado en EE. UU.
VIERNES, 28 de abril de 2023 (HealthDay News) -- La crisis de opioides de EE....
Comprehensive Approach Advised for Managing CV Risk in T2DM
FRIDAY, Jan. 14, 2022 (HealthDay News) -- A comprehensive approach is...
Opioid OD Rescue Drug Narcan Will Reach Drug Store Shelves Next Week
WEDNESDAY, Aug. 30, 2023 (HealthDay News) -- Narcan, a lifesaving medication...